Arvinas (ARVN) Net Cash Flow (QoQ) (2018 - 2026)
Powered by 
Analysis
Arvinas (ARVN) Net Cash Flow (QoQ) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 112.59% |
| Mar 31, 2026 | -234.30% |
| Dec 31, 2025 | 408.96% |
| Sep 30, 2025 | -139.53% |
| Jun 30, 2025 | 273.85% |
| Mar 31, 2025 | -227.45% |
| Dec 31, 2024 | 120.37% |
| Sep 30, 2024 | -212.43% |
| Jun 30, 2024 | 129.86% |
| Mar 31, 2024 | -212.98% |
| Dec 31, 2023 | 757.14% |
| Sep 30, 2023 | 158.33% |
| Jun 30, 2023 | -180.98% |
| Mar 31, 2023 | 195.32% |
| Dec 31, 2022 | -226.98% |
| Sep 30, 2022 | 30.74% |
| Jun 30, 2022 | 167.17% |
| Mar 31, 2022 | 68.79% |
| Dec 31, 2021 | -171.21% |
| Sep 30, 2021 | 170.67% |